Search Results

BioAegis Therapeutics is pleased to announce site recruitment for BTI-203, a Phase 2 study of recombinant human gelsolin for the treatment of Acute Respiratory Distress Syndrome .

BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce a second partnership with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.

BioAegis Therapeutics, Inc. announces that it will host a free webinar on the expanding spectrum of auto- and hyper- inflammatory diseases on Tuesday, May 23, 2023 at 2:00 pm Eastern Time.

BioAegis Therapeutics, Inc. announces publication of two new research studies exploring gelsolin’s role in type 2 diabetes, an inflammation-related metabolic disease.

BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human immune regulatory protein, reports 2022 highlights.

BioAegis Therapeutics, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for recombinant plasma gelsolin to proceed for the treatment of acute respiratory distress syndrome (ARDS).

BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory diseases based on a portfolio built around gelsolin technology, announces a new article on its novel host-directed approach.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system